ReviewOphthalmology and therapy2023
Artificial Intelligence for Diabetic Retinopathy Screening Using Color Retinal Photographs: From Development to Deployment.
Review in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 70 citations in OpenAlex.
- The AI-Driven Healthcare Value Framework-Rethinking Traditional Care Models in the Age of Automation.Healthcare (Basel, Switzerland) · 2026Article
- Deep Feature-Based Normality Modeling for Automated Out-Of-Distribution Detection in Sheep Retinal Fundus Images.Veterinary ophthalmology · 2026Article
- Automated diabetic retinopathy grading and screening using deep learning.International journal of retina and vitreous · 2026Article
- Artificial Intelligence-Based Medical Devices for Diabetic Retinopathy Screening in the European Union.Ophthalmology and therapy · 2026Review
- Article
- Global, Regional, and National Burden of Blindness due to Diabetic Retinopathy, 1990-2021.Ophthalmology and therapy · 2025Article
- A Narrative Review of Ethical Issues in the Use of Artificial Intelligence Enabled Diagnostics for Diabetic Retinopathy.Journal of evaluation in clinical practice · 2025Review
- RetinoDeep: Leveraging Deep Learning Models for Advanced Retinopathy Diagnostics.Sensors (Basel, Switzerland) · 2025Article
- Letter to the Editor: Equitable Deep Learning for Diabetic Retinopathy Detection Using Multidimensional Retinal Imaging With Fair Adaptive Scaling.Translational vision science & technology · 2025Article
- The Role of Artificial Intelligence in the Diagnosis and Management of Diabetic Retinopathy.Journal of clinical medicine · 2025Review
- IMI-Instrumentation for Myopia Management.Investigative ophthalmology & visual science · 2025Review
- Advancements in robotic surgery for vitreoretinal diseases: current trends and the future.Japanese journal of ophthalmology · 2025Review
- The efficacy of artificial intelligence in diabetic retinopathy screening: a systematic review and meta-analysis.International journal of retina and vitreous · 2025Article
- Shaping the Future of Healthcare: Ethical Clinical Challenges and Pathways to Trustworthy AI.Journal of clinical medicine · 2025Article
- Advances in intelligent recognition and diagnosis of skin scar images: concepts, methods, challenges, and future trends.Frontiers in medicine · 2025Review
- Diagnostic Accuracy of Automated Diabetic Retinopathy Image Assessment Software: IDx-DR and RetCAD.Ophthalmology and therapy · 2025Article
- Ensemble deep learning and EfficientNet for accurate diagnosis of diabetic retinopathy.Scientific reports · 2024Article
- Advancing healthcare with artificial intelligence: diagnostic accuracy of machine learning algorithm in diagnosis of diabetic retinopathy in the Brazilian population.Diabetology & metabolic syndrome · 2024Article
- Modern Approach to Diabetic Retinopathy Diagnostics.Diagnostics (Basel, Switzerland) · 2024Review
- Evaluation of Systemic Risk Factors in Patients with Diabetes Mellitus for Detecting Diabetic Retinopathy with Random Forest Classification Model.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR), a leading cause of preventable blindness, is expected to remain a growing health burden worldwide. Screening to detect early sight-threatening lesions of DR can reduce the burden of vision loss; nevertheless, the process requires intensive manual labor and extensive resources to accommodate the increasing number of patients with diabetes. Artificial intelligence (AI) has been shown to be an effective tool which can potentially lower the burden of screening DR and vision loss. In this article, we review the use of AI for DR screening on color retinal photographs in different phases of application, ranging from development to deployment. Early studies of machine learning (ML)-based algorithms using feature extraction to detect DR achieved a high sensitivity but relatively lower specificity. Robust sensitivity and specificity were achieved with the application of deep learning (DL), although ML is still used in some tasks. Public datasets were utilized in retrospective validations of the developmental phases in most algorithms, which require a large number of photographs. Large prospective clinical validation studies led to the approval of DL for autonomous screening of DR although the semi-autonomous approach may be preferable in some real-world settings. There have been few reports on real-world implementations of DL for DR screening. It is possible that AI may improve some real-world indicators for eye care in DR, such as increased screening uptake and referral adherence, but this has not been proven. The challenges in deployment may include workflow issues, such as mydriasis to lower ungradable cases; technical issues, such as integration into electronic health record systems and integration into existing camera systems; ethical issues, such as data privacy and security; acceptance of personnel and patients; and health-economic issues, such as the need to conduct health economic evaluations of using AI in the context of the country. The deployment of AI for DR screening should follow the governance model for AI in healthcare which outlines four main components: fairness, transparency, trustworthiness, and accountability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.